BlackRock
LENZ

BlackRock’s LENZ Therapeutics LENZ Stock Holding History

BlackRock’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Buy
2,292,121
+315,298
+16% +$2.54M ﹤0.01% 3531
2026
Q1 		$18.1M Buy
1,976,823
+284,817
+17% +$4M ﹤0.01% 3141
2025
Q4 		$27.1M Buy
1,692,006
+218,902
+15% +$6.38M ﹤0.01% 2916
2025
Q3 		$68.6M Buy
1,473,104
+40,643
+3% +$1.49M ﹤0.01% 2312
2025
Q2 		$42M Buy
1,432,461
+265,944
+23% +$7.23M ﹤0.01% 2553
2025
Q1 		$30M Buy
1,166,517
+10,892
+0.9% +$268K ﹤0.01% 2698
2024
Q4 		$33.4M Buy
1,155,625
+225,604
+24% +$6.88M ﹤0.01% 2714
2024
Q3 		$22.1M Sell
930,021
-30,023
-3% -$666K ﹤0.01% 2981
2024
Q2 		$16.6M Buy
960,044
+719,028
+298% +$12.6M ﹤0.01% 3089
2024
Q1 		$5.38M Sell
241,016
-10,415
-4% -$216K ﹤0.01% 3639
2023
Q4 		$4.61M Sell
251,431
-6,367
-2% -$105K ﹤0.01% 3723
2023
Q3 		$4.48M Buy
257,798
+13,539
+6% +$235K ﹤0.01% 3697
2023
Q2 		$4.45M Buy
244,259
+171,851
+237% +$3.43M ﹤0.01% 3766
2023
Q1 		$1.24M Sell
72,408
-1,962
-3% -$31.7K ﹤0.01% 4257
2022
Q4 		$1.73M Buy
74,370
+5,375
+8% +$125K ﹤0.01% 4192
2022
Q3 		$1.53M Sell
68,995
-720
-1% -$17.2K ﹤0.01% 4313
2022
Q2 		$1.34M Sell
69,715
-172,357
-71% -$3.84M ﹤0.01% 4413
2022
Q1 		$8.64M Buy
242,072
+68,891
+40% +$4.31M ﹤0.01% 3653
2021
Q4 		$15.1M Buy
173,181
+37,479
+28% +$3.11M ﹤0.01% 3436
2021
Q3 		$15.6M Buy
135,702
+120,905
+817% +$17.9M ﹤0.01% 3445
2021
Q2 		$3.18M Buy
+14,797
New +$2.58M ﹤0.01% 4072

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock's LENZ Position: Q2 2026 in Review

BlackRock increased its LENZ Therapeutics (LENZ) stake by 16% in Q2 2026, buying an estimated $2.54M and bringing the position to 2,292,121 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #3531.

BlackRock first reported a position in LENZ in Q2 2021 and has held it in 21 quarters since. The position peaked at $68.6M in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • BlackRock held 2,292,121 shares of LENZ Therapeutics worth $13M as of Q2 2026.
  • BlackRock bought 315,298 LENZ Therapeutics shares in Q2 2026, an estimated $2.54M.
  • LENZ Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3531 holding.
  • BlackRock first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • BlackRock's LENZ Therapeutics position peaked at $68.6M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.